Compositions and methods for the treatment of cancer

Clonal Replica Tumors with deep-sequencing analysis help predict cancer response to immunotherapy by identifying genomic alterations at the 6q23.2-25.1 region, addressing tumor heterogeneity and guiding personalized treatment strategies for improved therapeutic outcomes.

WO2026151566A1 Publication Date: 2026-07-16BOARD OF RGT THE UNIV OF TEXAS SYST
0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2025/059453
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-01-10
Filing Date
2025-12-12
Publication Date
2026-07-16

AI Technical Summary

Technical Problem

Current cancer therapies, particularly immunotherapies like immune checkpoint blockade (ICB), face challenges in effectively addressing tumor heterogeneity, leading to variable patient responses due to the complex evolutionary dynamics and genomic diversity within tumors, especially in aggressive cancers like pancreatic ductal adenocarcinoma (PDAC), where resistance to treatment is common.

Method used

The use of Clonal Replica Tumors (CRTs) coupled with deep-sequencing analysis to identify and characterize clonal lineages within tumors, allowing for the determination of copy numbers and genomic alterations at the 6q23.2-25.1 region, guiding the selection of appropriate therapies such as immunotherapy, chemotherapy, or other treatments based on specific genomic profiles.

Benefits of technology

This approach provides a systematic method to predict cancer response to immunotherapy and tailor treatment strategies, improving therapeutic efficacy by identifying favorable or adverse genomic alterations that influence treatment outcomes.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present disclosure provides methods and compositions for predicting response to an immunotherapy and treating cancer comprising determining a copy number or genomic alteration status of the cancer at a genomic region within or genetically linked to human chromosome 6q23.2-25.1 or within or genetically linked to a gene comprised within the genomic region. The present disclosure further provides methods and compositions for treating cancer using the identification of the copy number or genomic alteration status to administer a treatment regimen.
Need to check novelty before this filing date? Find Prior Art